Nospharma is a preclinical therapeutics company developing innovative treatments for rare genetic neurological disorders. Their lead candidate, NOS‑01, will now be tested in FRAXA’s preclinical models for Fragile X Syndrome (FXS), one of the most common inherited causes of intellectual disability and a condition that currently has no approved therapies.